Stay updated on Pembrolizumab with BCG post-ablation in UUTTCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG post-ablation in UUTTCC Clinical Trial page.

Latest updates to the Pembrolizumab with BCG post-ablation in UUTTCC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a study on Pembrolizumab for high-risk superficial upper urinary tract transitional cell carcinoma, while adding a new version revision and a brief mention of the study's location.SummaryDifference53%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab with BCG post-ablation in UUTTCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG post-ablation in UUTTCC Clinical Trial page.